En español
NIDA

Menu

Publications

Quick Links

National Advisory Council Agenda

132nd Meeting of the National Advisory Council on Drug Abuse

Neuroscience Center - Conference Rooms C & D
6001 Executive Boulevard, Bethesda, MD.

Individuals with disabilities who need sign language interpreting and/or other reasonable accommodations to participate in this event, should contact Gillian Acca via email or phone at 301-827-5843 or through the Federal Relay (1-800-877-8339). Requests should be made at least five days in advance of the workshop.

May 14, 2019

Closed Session

This meeting is closed to the public in accordance with the provisions set forth in section 552b{c}(4) and 552b{c}(6), Title 5, U.S. Code and section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2).

9:00 a.m. Call to Order
Nora Volkow, M.D. Director, NIDA

Review of Policy and Procedures
Susan Weiss, Ph.D.
Executive Secretary
National Advisory Council on Drug Abuse
Director, Division of Extramural Research, NIDA
9:15 a.m.

Council Review of Grant Applications
Nora Volkow, M.D., Director, NIDA

Division of Epidemiology, Services, and Prevention Research (DESPR)
Carlos Blanco, M.D., Ph.D., Director

Office of Translational Initiatives and Program Innovationa (OTIPI)
Elena Koustova, Ph.D., M.B.A., Director

Division of Therapeutics and Medical Consequences (DTMC)
Iván Montoya, M.D., Deputy Director

Division of Neuroscience and Behavior (DNB)
Rita Valentino, Ph.D., Director

10:15 a.m. Break

Videocast: https://videocast.nih.gov/summary.asp?live=31997&bhcp=1

Open Session

10:30 a.m. Welcome and Opening Remarks
Nora Volkow, M.D. Director, NIDA
10:45 a.m. Director's Report
Nora Volkow, M.D. Director, NIDA
11:45 a.m. Discussion
Council Members
12:15 p.m. Lunch Break
1:30 p.m. Points to Consider Regarding Tobacco Industry Funding: Implications for Companies that Produce Electronic Nicotine Devices (ENDs)​
Susan Weiss, Ph.D., Director, Division of Extramural Research, Executive Secretary, NACDA
2:00 p.m. NIDA SBIR and STTR: building successful programs for a niche market 
Elena Koustova, Ph.D., M.B.A, Director, Office of Translational Initiatives and Program Innovations (OTIPI), NIDA
2:45 p.m. Necessity is the Mother of Invention:  A Personal Perspective on Antimicrobial Resistance and A Forgotten Cure
Steffanie Strathdee, Ph.D., Associate Dean of Global Health Sciences, University of California, San Diego
3:30 p.m.

Concept Clearances

  • Step Up for Opioid Use Disorder (OUD): Translational Stepladder Initiative
    Ramachandran Arudchandran, Ph.D., Health Scientist Administrator, OTIPI
  • Renewal of the National Drug Abuse Treatment Clinical Trials Network (CTN)
    Geetha Subramaniam, M.D. Deputy Director, Center for Clinical Trials Network
  • Strategic Alliances for Medications Development to Treat Substance Use Disorders
    Iván Montoya, M.D., Deputy Director, Division of Therapeutics and Medical Consequences (DTMC)
  • Grand Opportunity in Medications Development for Substance Use Disorders
    Iván Montoya, M.D., Deputy Director, Division of Therapeutics and Medical Consequences (DTMC)
4:00 p.m. Public Comments
4:15 p.m. Adjourn

This page was last updated January 2019